General Information
Paliperidone Palmitate is an atypical antipsychotic, indicated for the treatment of schizophrenia and schizoaffective disorder in its finished dosage. Paliperidone is the primary active metabolite of risperidone. The mechanism of action is likely to be similar to risperidone. The manufacturing of paliperidone palmitate involves combining paliperidone API, the active component, with palmitic acid to form the palmitate ester. Paliperidone form of palmitate ester is formulated prolonged release suspension and acts as long lasting Paliperidone into the bloodstream during of time 1, 3 and 6 months.
About the API
Systematic name
[(9R)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl] hexadecanoate
Trade name(s)
Invega Sustenna/ Invega Trinza
Technology
Synthetic
Molecular Formula
C39H57FN4O4
Molecular Weight
664.9 g/mol
Therapeutic category
Neurology-Psychiatry
Available formulations
Injectables